Citation: Morisco, F.; Federico, A.; Marignani, M.; Cannavò, M.; Pontillo, G.; Guarino, M.; Dallio, M.; Begini, P.; Benigno, R.G.; Lombardo, F.L.; et al. Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. Cancers 2021, 13, 3810. https://doi.org/10.3390/cancers13153810

Academic Editors: John Koskinas and David A. Geller

Received: 21 May 2021
Accepted: 25 July 2021
Published: 29 July 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Experience with new direct-acting antiviral agents (DAAs) treatment for chronic HCV infection has shown that more than 95% of treated subjects, even those with liver cirrhosis,
achieves sustained virological response (SVR), i.e., clearance of the virus [1]. This rate of cure is much higher than the corresponding rate of <20% obtained in cirrhotic patients previously treated with Interferon-based (IFN) therapies [2], generating a great increase in subjects cured of HCV infection.

Several studies compared SVR versus no-SVR cases to assess the rate of independent predictors for liver-related events. Cirrhotic subjects who achieved SVR after DAAs treatment had significantly lower rates of liver-related events, including de novo HCC development, as compared to those who did not achieve SVR [3–8]. Nonetheless, cirrhotic subjects who achieved SVR continued to develop liver-related events, albeit at a lower rate [9]. There is limited information on predictors of unfavorable outcomes after successful viral eradication.

Two US retrospective studies [10,11] and one Italian retrospective study [12] focused only on HCC occurrence. Only a Spanish prospective study [13] evaluated predictors of liver events related to portal hypertension (ascites, variceal bleeding, hepatorenal syndrome, hepatic encephalopathy) and HCC in the subgroup of “compensated advanced chronic liver disease” (cACLD), a population free of previous decompensation events but characterized by the presence of signs of portal hypertension [14]. This population is of obvious interest, but it does not represent all cirrhotic cases.

To further expand the currently limited information on this issue, we evaluated the non-serological baseline predictors of liver-related events’ development in cirrhotic subjects (regardless of Child–Pugh stage) achieving SVR after DAAs therapy in a prospective manner.

2. Results
2.1. Overall Cohort

A total of 706 HCV-RNA-positive cirrhotic patients started DAAs therapy. SVR was confirmed in 687 (97.3%) of them. A total of 66 subjects had at least one liver-related event during a mean follow-up of 28.4 ± 5 months: 61 (8.9%) in the SVR group and 5 (26.3%) in the no-SVR group. Ten subjects (nine in the SVR group; median follow-up 1.25 years, range 0.7–1.5) were lost to follow-up; none of them, however, reported liver-related events up to the last observation performed. The Kaplan–Meier cumulative incidence curves of any event by SVR status are shown in Figure 1 (p < 0.003 by log-rank test).

![Figure 1. Cumulative incidence of any event (deaths for hepatic and non-hepatic cause, liver transplantation, liver decompensation, and HCC) in cirrhotic subjects according to SVR (Kaplan–Meier estimates).](image-url)

The incidence rate of any event (i.e., liver-decompensation, HCC, and death for any cause) per 100 person-years was 3.7 (95% CI 2.9–4.8) in the SVR group and 12.3 (95% CI 5.1–29.6) in the no-SVR group. The relative rate (RR) of any event for subjects who did not achieve SVR compared to subjects who achieved SVR was 3.3 (95% CI 1.3–8.2).
In SVR patients, eight liver-related deaths were recorded, and two were recorded in no-SVR patients. The incidence rate per 100 person-years was 0.5 (95% CI 0.2–1.0) in the SVR group and 4.3 (95% CI 1.1–17.2) in the no-SVR group. The RR or incidence rate ratio for subjects who did not achieve SVR compared to subjects who achieved SVR was 9.0 (95% CI 1.9–42.6). See Table S1A.

2.2. SVR Cohort

The baseline characteristics of the 687 subjects who achieved SVR are shown in Table 1. The male/female ratio was 1.2; the mean age was 64 years. More than half of them (53.4%) reported previous IFN therapy. Genotype 1 was predominant (80.1% of cases). As many as 92.7% of cases had Child–Pugh A stage cirrhosis, 7.3% Child–Pugh B, and none Child–Pugh C. Liver stiffness was measured in 567 (82.5%) subjects; most of them (70.6%) had a basal value < 20 kPa.

Table 1. Baseline characteristics of cirrhotic subjects who attained SVR and those who did not after treatment with DAAs.

| Baseline Characteristics | Total Subjects (n = 706) | SVR (n = 687) | Non-SVR (n = 19) | p       |
|--------------------------|--------------------------|---------------|------------------|---------|
| Sex                      |                          |               |                  |         |
| Males                    | 387 (54.8)               | 374 (54.4)    | 13 (68.4)        | 0.227   |
| Females                  | 319 (45.2)               | 313 (45.6)    | 6 (31.6)         |         |
| Sex ratio                | M/F                      | 1.2           | 1.2              | 2.2     |
| Age Distribution (years) | ≤50                      | 101 (14.3)    | 98 (14.3)        | 3 (15.8) |
|                         | 51–65                    | 239 (33.9)    | 236 (34.3)       | 3 (15.8) |
|                         | >65                      | 366 (51.8)    | 353 (51.4)       | 13 (68.4)|
| Mean age (SD)            | ≥20                      | 64.1 (11.7)   | 64.0 (11.7)      | 64.9 (11.8) |
| Previous IFN treatment   |                          | 379 (53.7)    | 367 (53.4)       | 12 (63.2) |
| Mean Child–Pugh* A       | 651 (92.2)               | 637 (92.7)    | 14 (73.7)        | 0.002   |
| Mean Child–Pugh B        | 55 (7.8)                 | 50 (7.3)      | 5 (26.3)         |         |
| Mean Child–Pugh score (SD)|<20                      | 5.3 (0.7)     | 5.3 (0.7)        | 5.7 (1.0)|
|                         | ≥20                      | 411 (70.9)    | 400 (70.6)       | 11 (84.6) |
| Mean liver stiffness     | 19.2 (7.9)               | 19.3 (8.0)    | 16.7 (3.3)       | 0.253   |
| Genotype                 | 567 (80.3)               | 550 (80.1)    | 17 (89.5)        |         |
|                         | 96 (13.6)                | 95 (13.8)     | 1 (5.3)          |         |
|                         | 27 (3.8)                 | 27 (3.9)      | 0                | 0.578   |
|                         | 15 (2.1)                 | 14 (2.0)      | 1 (5.3)          |         |
|                         | 1 (0.1)                  | 1 (0.2)       | 0                |         |
| DAAs Therapy             | SOF                      | 60 (8.5)      | 58 (8.4)         | 2 (10.5) |
|                         | SOF + other              | 460 (65.1)    | 446 (65.0)       | 14 (73.7) |
|                         | 3D                       | 160 (22.7)    | 157 (22.8)       | 3 (15.8) |
|                         | 2D                       | 26 (3.7)      | 26 (3.8)         | 0       |
| Ribavirin                | 316 (44.8)               | 307 (44.7)    | 9 (47.4)         | 0.817   |

* None of the subjects were Child–Pugh C; ** Stiffness measurements performed in 567 (82.5%) subjects.

In total, 15.4% (106/687) of SVR subjects had an improvement in the Child–Pugh score at the last evaluation in comparison to the baseline value. In particular, 72.7% of Child–Pugh B patients had an improvement in liver function, obtaining a Child–Pugh score of A after SVR.

2.3. Occurrence of Events in SVR Cohort

The incidence rate × 100 person-years was 1.2 for overall death (0.5 for hepatic and 0.7 for not-hepatic cause), 1.7 for liver decompensation, 1.6 for HCC, and 0.1 for liver transplantation. The overall incidence of any event was 3.7 × 100 person-years (Table 2).
Table 2. Number and incidence rate per 100 person-years of main events during the 24 months of follow-up after the end of treatment with DAAs in patients who attained SVR.

| Events                              | N   | Incidence Rate Per 100 p/y |
|-------------------------------------|-----|----------------------------|
| Overall death                       | 20  | 1.2 (0.8–1.8)              |
| Death due to hepatic cause          | 8   | 0.5 (0.2–1.0)              |
| Death due to non-hepatic cause      | 12  | 0.7 (0.4–1.3)              |
| Any liver decompensation *          | 28  | 1.7 (1.2–2.4)              |
| HCC #                               | 26  | 1.6 (1.1–2.3)              |
| Liver transplantation               | 1   | 0.1 (0.0–0.4)              |
| Any event §                         | 61  | 3.7 (2.9–4.8)              |

* Ascites, hepatic encephalopathy, upper gastrointestinal bleeding, SPB (spontaneous bacterial peritonitis); # five subjects also developed liver decompensation; § includes all the events listed in the table.

2.4. Decrease in Liver Stiffness Measurement (Delta LSM)

At the end of follow-up, liver stiffness was measured in 490 (86.4%) of the 567 subjects who had a liver stiffness measurement at the beginning of the study. Of them, 258 (52.6%) had a ≥20% decrease in liver stiffness value as compared to baseline. The only baseline factor associated with a liver stiffness decrease of ≥20% was a genotype different from 1 (p < 0.04) (Table 3). Comparing subjects with Delta LSM of ≥ or <20% of the basal value, those below this cut-off did not appear to be at a higher risk of liver decompensation (incidence rate 0.6 vs. 0.5; RR 1.2, 95% CI = 0.3–5.4) or of HCC occurrence (incidence rate 0.8 vs. 0.3; RR 2.3, 95% CI = 0.4–11.8). See Table S1B.

Table 3. Frequency of baseline characteristics of SVR subjects according to a ≥20% decrease in liver stiffness value after 24 months of follow-up.

| Characteristics | Decreased Stiffness | | | |
|-----------------|---------------------|-----------------|---------------------| |
|                 | Yes (n = 258) | No (n = 232) | p-Value * |
|                 | n (%)       | n (%)       |         |
| Sex             |             |             |         |
| M               | 140 (54.3)  | 117 (50.4)  | 0.396   |
| F               | 118 (45.7)  | 115 (49.6)  |         |
| Age (years)     |             |             |         |
| <65             | 124 (48.1)  | 118 (50.9)  | 0.536   |
| ≥65             | 134 (51.9)  | 114 (49.1)  |         |
| Child–Pugh A    | 250 (96.9)  | 225 (97.0)  | 0.957   |
| B               | 8 (3.1)     | 7 (3.0)     |         |
| Genotype        |             |             |         |
| 1               | 200 (77.5)  | 197 (84.9)  | 0.037   |
| other           | 58 (22.5)   | 35 (15.1)   |         |

* Chi-squared test. Limited to subjects who had stiffness measurement at baseline and at the end of follow-up. Subjects who died due to a hepatic or non-hepatic cause and who underwent liver transplantation were excluded.

2.5. Basal Predictors of Liver-Related Events

The crude and adjusted HR for the association of non-serological baseline characteristics of SVR subjects with liver-related events are shown in Table 4. Liver stiffness ≥20 kPa (HR 4.0; 95% CI 1.1–14.1) and a genotype different from 1 (HR 7.5; 95% CI 2.1–27.3) were both independent predictors of liver decompensation, while liver stiffness ≥20 kPa (HR 7.2; 95% CI 1.9–26.7) was the only independent predictor of HCC development. After the analyses for competing risks (i.e., considering death for any cause of a competing event), the association of liver-related events with the considered variables did not change. The cumulative incidences of liver decompensation and HCC according to the value of liver stiffness at baseline are shown in Figure 2. The incidence rate of liver decompensation per 100 person-years was 0.4 (95% CI 0.1–1.08) in subjects with basal LSM value < 20 kPa, as compared to 2.2 (95% CI 1.2–4.3) in those above this cut-off (RR = 5.5) (95% CI = 1.7–17.8) (Figure 2A); the incidence rate of HCC was 0.3 (95% CI 0.1–0.9) in subjects with basal LSM value < 20 kPa, as compared to 2.5 (95% CI 1.4–4.7) in those above this cut-off (RR = 8.3) (95% CI 2.3–30.2) (Figure 2B). Finally, Figure 3 summarizes the study flowchart with the main results.
Table 4. Crude and adjusted hazard ratios (HR) for the association of baseline characteristics with liver decompensation and HCC in cirrhotic subjects who attained SVR after DAAs therapy (univariate and multivariate Cox model).

| Characteristics | Liver Decompensation | HCC |
|-----------------|----------------------|-----|
|                 | HR<sub>crude</sub> (95% IC) | p  | HR<sub>adj</sub> (95% IC) | p  | HR<sub>crude</sub> (95% IC) | p  | HR<sub>adj</sub> (95% IC) | p  |
| Sex             |                       |    |                           |    |                             |    |
| F               | 1                     |    |                           |    |                             |    |
| M               | 1.0 (0.5–2.2)         | 0.931 |                           | -  | 2.1 (0.9–5.2)               | 0.080 | 1.6 (0.5–5.2) | 0.436 |
| Age (y)         |                       |    |                           |    |                             |    |
| <65             | 1                     |    |                           |    |                             |    |
| ≥65             | 2.6 (1.1–6.2)         | 0.030 | 3.2 (0.8–12.0)            | 0.091 | 1.6 (0.7–3.6)               | 0.248 | -             | -     |
| Child–Pugh      |                       |    |                           |    |                             |    |
| A               | 8.0 (3.5–18.2)        | <0.001 | 3.8 (0.4–34.4)            | 0.236 | 2.6 (0.9–7.7)               | 0.079 | 2.8 (0.6–12.8) | 0.191 |
| B               | 3.8 (1.1–13.4)        | 0.034 | 4.0 (1.1–14.1)            | 0.031 | 8.3 (2.3–30.1)              | 0.001 | 7.2 (1.9–26.7) | 0.003 |
| Stiffness       |                       |    |                           |    |                             |    |
| <20             | 3.8 (1.2–5.6)         | 0.020 | 7.5 (2.1–27.3)            | 0.002 | 1.7 (0.7–4.0)               | 0.253 | -             | -     |
| ≥20             | 8.0 (3.5–18.2)        | <0.001 | 3.8 (0.4–34.4)            | 0.236 | 2.6 (0.9–7.7)               | 0.079 | 2.8 (0.6–12.8) | 0.191 |
| Genotype        |                       |    |                           |    |                             |    |
| 1               | 1                     |    |                           |    |                             |    |
| other           | 2.6 (1.2–5.6)         | 0.020 | 7.5 (2.1–27.3)            | 0.002 | 1.7 (0.7–4.0)               | 0.253 | -             | -     |
| DAAs therapy    |                       |    |                           |    |                             |    |
| SOF-based       | 1                     |    |                           |    |                             |    |
| other           | 0.5 (0.2–1.5)         | 0.213 | -                         | -     | 0.6 (0.2–1.6)               | 0.326 | -             | -     |

Figure 2. Cumulative incidence of liver decompensation (A) and HCC (B) in cirrhotic subjects according to the value of stiffness at baseline (Kaplan–Meier estimates).
Figure 3. Study flowchart with main results.

3. Discussion

Until now, the largest published cohort of cirrhotic patients treated with DAAs outside a liver transplant setting is the study reported by Cheung et al. [15], which analyzed 406 patients, most of them Child–Pugh B (41 patients were Child–Pugh C), and followed-up for 15 months. The majority of patients had a reversal of liver decompensation after DAAs therapy, with no evidence of an increased risk of liver malignancy. Our study proposes instead, with a prospective design, to evaluate the predictors of any liver-related event (decompensation and HCC) in cirrhotic subjects in Child–Pugh stage A and B achieving SVR after oral antiviral therapy with follow-up extended to 24 months for all subjects.

The main finding of the present study is the role of baseline liver stiffness ($\geq 20$ kPa) as an independent predictor of liver-related event development. Compared to subjects with baseline liver stiffness <20 kPa, those who had an LSM above this cut-off showed a four-fold higher risk of liver decompensation and a seven-fold higher risk of HCC after adjustment for the confounding effect of baseline variables by the Cox regression model.

Liver stiffness measurement by transient elastography is an accurate indirect, non-invasive method to assess liver fibrosis grade [16], a strong risk factor for HCC and for portal hypertension. In fact, LSM has been shown to have good accuracy in predicting the presence of cirrhosis [17] and clinically significant portal hypertension [18–20], as confirmed by the Baveno VI consensus document [14].

An increased basal LSM value, evaluated as a continuous variable, has been associated with an increased risk of HCC in several studies [12,21–26]. In a Japanese study, when compared to basal LSM $\leq 10$ kPa, the adjusted hazard ratio for HCC development result
was 16.7 when LSM was between 10.1 kPa and 15 kPa, 20.9 when LSM was between 15.1 kPa and 20 kPa, 25.6 when LSM was between 20.1 kPa and 25 kPa, and finally, the result was 45.5 when LSM was >25 kPa after adjustment for other significant factors for HCC [21].

The cut-off of 20 kPa identified in the present study is in line with the data produced by Lens et al., who identified a cut-off of 21 kPa to separate patients with and without benefit from SVR in the presence of clinically significant portal hypertension [27].

In agreement with our findings, a previous retrospective Italian study [12] using a higher basal LSM cut-off (≥30 kPa) showed an increased, although marginally associated, risk of HCC occurrence (HR 1.03; 95% CI = 1.01–1.06) during a median follow-up of 24 months. Conversely, a Spanish study [13] identifying a similar basal LSM cut-off (≥20 kPa) failed to show an increased risk of HCC occurrence. This discrepancy may be explained by a selection bias: the Spanish study recruited only a subset of cirrhotic subjects, i.e., those with well-compensated disease, while our survey enrolled even cirrhotic patients with more advanced disease (i.e., Child–Pugh A with prior decompensation and Child–Pugh B).

Change in liver stiffness value over time (Delta LMS) has been proposed as an accurate and reliable predictor of liver decompensation [28] and HCC [29]. Unfortunately, in both this study and the Spanish study [13], a ≥20% decrease in Delta liver stiffness at the end of follow-up was not associated with a reduced risk of HCC and liver decompensation. The relative early change of LSM probably reflects a greater improvement in liver inflammation than in fibrosis, which may require longer follow-up to be observed.

Compared to Child–Pugh A cases, the enrolled Child–Pugh B cases did not show a higher risk of subsequent liver decompensation or HCC. Additionally, most subjects showed an improvement in liver function, becoming Child–Pugh A with a subsequent decreased risk of liver-related events. Conversely, a recent retrospective study has shown that in patients with chronic HCV infection, DAAs-induced SVR was associated with a reduced risk of liver-related events in Child–Pugh A subjects but not in those with Child–Pugh B/C cirrhosis [30]. These discrepant findings may be explained by the lower sample size of Child–Pugh B cirrhosis in our study (50 vs. 149), which hampered detection of potential associations. Moreover, in our study, Child–Pugh C subjects were absent, which generated an underestimation of events in subjects with baseline decompensated cirrhosis.

Our study shows low incidence rates × 100 p/y of liver-related events in SVR cirrhotic subjects. The incidence estimate rate of HCC is 1.6 × 100 p/y; it is similar to the 1.5 rate × 100 p/y reported in the recent prospective Spanish study [13], to the 1.18 rate × 100 p/y reported in the Italian multicenter prospective study by Romano et al., [31] and to the 0.9 rate × 100 p/y reported in a recent retrospective US study [2], confirming the favorable impact of oral antiviral therapy on this severe outcome.

In our study, the incidence rate × 100 person-years of follow-up was 1.7 for liver decompensation events. In particular, 28 patients (4%) developed at least one liver decompensation event (in detail: 16 ascites, 15 variceal bleeding, 5 hepatic encephalopathies, 1 SBP). These data are in line with those of Cheung et al., who showed that liver-related events were most frequent during the treatment period and decreased over time with 16/317 SVR patients (5%) experiencing decompensation in 6–15 months after DAA treatment [15].

The main limitation of this study is the exclusion of Child–Pugh C patients, who, according to the Italian DAAs prescription rules, are not suitable for treatment outside the liver transplantation waiting list. As these subjects are at higher risk of liver-related events, their exclusion may have generated an underestimation of this outcome.

On the other hand, the present study is characterized by several strong points that are worth underlining. First, and most importantly, its prospective design allows for more accurate ascertainment than retrospective studies, which may be affected by selection and ascertainment biases. Second, the large patient cohort, the consecutive enrollment of cases, and the long follow-up (28.4 ± 5 months) represent a unique example in the literature.
Third, the cut-off of basal LSM adopted for enrolment (≥14 kPa) allows excluding patients with bridging fibrosis, a subgroup at a lower risk of liver-related events as compared to cirrhotic ones. Finally, the large proportion (86.5%) of subjects who had a coupled liver stiffness measurement at baseline and at the end of follow-up provided enough statistical power to detect the influence of Delta LSM on the occurrence of liver-related events.

4. Materials and Methods

4.1. Study Design

This was a prospective cohort study. All cirrhotic subjects receiving DAAs therapy were followed for 24 months after confirming SVR (see paragraph SVR). At the end of follow-up, outcome event rates were compared between SVR and no-SVR. Among SVR cases, a further comparison was made among those who developed and those who did not develop liver-related events. In this latter group, adjusted hazard ratios (HR) were calculated to evaluate independent non-serological baseline event predictors (see Statistical Analysis).

4.2. Target Population

All consecutive HCV-RNA positive cirrhotic subjects, ≥18 years of age, and Child–Pugh stage A and B candidates for DAAs therapy were enrolled in this prospective study between 1 November 2015 and 31 October 2017 in four tertiary centers (one in Rome, two in Naples, and one in Catania).

The diagnosis of liver cirrhosis was based on the presence of the peculiar clinical, biochemical, ultrasound signs [32], and transient elastometry performed by Fibroscan [16], with a liver stiffness cut-off value ≥14 kPa. Exclusion criteria were: history of prior HCC, prior liver transplantation, HBV and/or HIV co-infections, history of alcohol consumption (previous and/or continuing), and Child–Pugh C score since treatment was not reimbursed by the Italian National Health System outside the liver transplantation waiting list [33].

A web database recorded information on baseline demographic, clinical, and treatment characteristics of patients; treatment outcome, type, and timing of event occurrences were also registered.

Subjects signed informed consent to participate. The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the ethical board of the promoting center (Federico II University of Naples).

4.3. Definition of SVR

SVR was defined as undetectable HCV-RNA at 12 weeks after the end of therapy using the Cobas AmpliPrep/Cobas TaqMan (Roche Molecular Diagnostics, Pleasanton, CA, USA; lower limit of detection 15 IU/mL).

4.4. Liver Stiffness Measurement

Liver stiffness measurement (LSM) was performed using transient elastography at baseline and at the end of follow-up by a single experienced operator in each center and according to the usual standard procedure. Improvement in LSM at the end of follow-up (Delta LSM) was defined as a decrease of ≥20% from basal LSM value.

4.5. Outcomes and Follow-Up

The main outcome of the study was the analysis of liver-related events development after SVR achievement. Liver-related events were defined as:

- Recurrence or new-onset of 1. ascites, 2. variceal bleeding, 3. spontaneous bacterial peritonitis, 4. hepatic encephalopathy for Child–Pugh A and B patients;
- Occurrence of de novo HCC for Child–Pugh A and B patients;
- In Child–Pugh B patients, worsening of a pre-existing symptom of decompensated cirrhosis (i.e., an increased dose of diuretics, the addition of rifaximin for hepatic encephalopathy, or hospital admission for a new liver failure event).
Any liver-related event that developed during follow-up was registered in the database. Mortality was also registered as liver-related or not liver-related. HCC surveillance was performed with ultrasound every 6 months according to standard clinical practice. In the case of liver focal lesions identified by ultrasound, HCC was confirmed by imaging (computed tomography and/or magnetic resonance imaging) and/or biopsy examination according to international guidelines [34].

The at-risk period for each subject was defined by the time from starting DAAs treatment until the onset of the event. Events occurring before the end of antiviral treatment were not included in the analysis (i.e., 12 subjects: 1 variceal bleeding, 3 ascites, 1 hepatic encephalopathy, 7 HCC). Follow-up lasted 24 months after SVR.

Data were censored when individuals died or were lost during follow-up. Patients lost during follow-up were registered as alive until the last day of observation.

4.6. Statistical Analysis

Continuous variables were expressed as mean and standard deviation (SD), and qualitative variables as absolute frequency and percentage. Differences in proportions were evaluated by the Chi-square test; a $p$-value < 0.05 was considered significant.

The relative rate (RR) of liver-related events was calculated as a ratio of the incidence rates of events in the overall cohort of subjects according to the SVR status and in the SVR cohort according to the baseline LSM and its decrease from baseline to the end of follow-up by at least 20%.

The Kaplan–Meier method was used to estimate the cumulative incidence of events. Comparison of survival curves between groups was performed using the log-rank (Mantel–Cox) test.

Incidence density rates of liver-related events per 100 person-years, with 95% confidence intervals (95% CI), were provided.

In SVR patients, univariate and multivariate Cox regression analyses were used to identify baseline variables (age, sex, Child–Pugh class, genotype, and stiffness value) associated with the development of any liver-related event or HCC (outcome variables). Variables with a threshold $p$-value lower than 0.10 at univariate analysis were included in the multivariate model. A sensitivity analysis was performed using Cox proportional hazards regression accounting for the competing risk [35], considering deaths as competing risk events. Assumptions of proportional hazards were tested using Schoenfeld residuals.

The association of baseline characteristics in SVR subjects with an LSM decrement by $\geq 20\%$ from baseline to the end of follow-up was assessed by a logistic model.

Statistical analyses were performed using STATA 14.2 statistical software (StataCorp, College Station, TX, USA).

5. Conclusions

In conclusion, this study identified a basal LSM cut-off of $\geq 20$ kPa as an independent predictor of liver-related events in cirrhotic subjects achieving SVR after DAAs therapy. Studies with a longer follow-up in this setting are warranted to further evaluate the potential role of Delta LSM on the occurrence of liver-related events.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13153810/s1: Table S1. Incidence rate (IR) per 100 person-years and relative rate (RR) of liver-related events in SVR vs. no SVR cases (A), of liver decompensation and HCC in SVR according to Delta LSM (B), and basal LSM value (C) in an Italian prospective study.

Author Contributions: T.S., F.M., A.F. and M.M. were involved in study concept and design. M.G., G.P., M.D., M.C., P.B. and R.G.B. were involved in acquisition of data. T.S., A.F., M.M. and F.M. were involved in analysis and interpretation of data. T.S., F.M. and M.G. were involved in drafting of the manuscript. T.S., F.M., A.F., M.M. and M.G. performed critical revision of the manuscript for important intellectual content. F.L.L. performed statistical analysis. T.S. and F.M. were involved in study supervision. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of University Federico II of Naples (protocol code 245/13; date of approval 5 March 2014).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Falade-Nwulia, O.; Suarez-Cuervo, C.; Nelson, D.R.; Fried, M.W.; Segal, J.B.; Sulkowsky, M.S. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. *Ann. Int. Med.* 2017, 166, 637–648. [CrossRef]
2. Everson, G.T.; Jensen, D.M.; Graico Bain, V.G.; Ehrinpreis, M.N.; Albert, D.; Joh, T.; Witt, K. Efficacy of interferon treatment for patients with chronic hepatitis C; comparison of response in cirrhotics, fibrotics, or nonfibrotics. *Hepatology* 1999, 30, 271–276. [CrossRef]
3. Waziry, R.; Hajariizadeh, B.; Grebely, J.; Amin, J.; Law, M.; Danta, M.; George, J.; Dore, G.J. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy; a systematic review, meta-analysis and meta-regression. *J. Hepatol.* 2017, 67, 1204–1212. [CrossRef] [PubMed]
4. Singh, S.; Nautyal, A.; Loke, Y.K. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma. A systematic review and meta-analysis. *Frontline Gastroenterol.* 2018, 9, 262–270. [CrossRef] [PubMed]
5. Kanwal, F.; Kramer, J.R.; Asch, S.M.; Chayanapatkul, M.; Cao, Y.; El-Serag, H.B. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. *Gastroenterology* 2017, 153, 996–1005. [CrossRef]
6. Calvaruso, V.; Cabibbo, G.; Cacciola, I.; Pettà, S.; Madonia, S.; Bellia, A.; Tinelli, F.; Distefano, M.; Licata, A.; Giannitrapani, L.; et al. Incidence of hepatocellular carcinoma in patients with HCV associated cirrhosis treated with Direct-acting antiviral agents. *Gastroenterology* 2018, 155, 411–421. [CrossRef]
7. Backus, L.I.; Berlperio, P.S.; Shahoumain, T.A.; Mole, A. Impact of sustained virological response with Direct-Acting antiviral treatment on mortality in patients with advances liver disease. *Hepatology* 2019, 69, 487–497. [CrossRef]
8. Butt, A.A.; Van, P.; Shaikh, O.S.; Lo Re, V.; Abou-Samra, A.B.; Sherman, K.E. Treatment of HCV reduces viral hepatitis associated liver-related mortality in patients: An ARCHIVES study. *J. Hepatol.* 2020, 73, 277–284. [CrossRef]
9. Guarino, M.; Morisco, F.; Valvano, M.R.; Ippolito, A.M.; Librandi, M.; Andriulli, N.; Greco, M.; Amoruso, A.; Iacobellis, A.; Niro, G.; et al. Systematic review: Interferon-free regimens for patients with HCV-related Child C cirrhosis. *Aliment. Pharmacol. Ther.* 2017, 45, 1193–1200. [CrossRef] [PubMed]
10. Ioannu, G.N.; Beste, L.A.; Green, P.K.; Singal, A.G.; Tapper, E.B.; Waljee, A.K.; Kaplan, D.E.; Taddei, T.H. Increased risk of hepatocellular carcinoma persist up to 10 years after HCV eradication in patients with baseline cirrhosis or High FIB-4 scores. *Gastroenterology* 2019, 157, 1264–1278. [CrossRef] [PubMed]
11. Kanwal, F.; Kramer, J.R.; Asch, S.M.; Cao, Y.; Li, L.; El-Serag, H.B. Long-term risk of hepatocellular carcinoma in HCV patients treated with Direct Acting antiviral agents. *Hepatology* 2020, 71, 44–55. [CrossRef] [PubMed]
12. Degasperi, E.; D’Ambrosio, R.; Iavarone, M.; Sangiovanni, A.; Aghemo, A.; Soffredini, R.; Borghi, M.; Lunghi, G.; Colombo, M.; Lampertico, P. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. *Clin. Gastroenterol. Hepatol.* 2019, 17, 1183–1191. [CrossRef] [PubMed]
13. Pons, M.; Rodriguez-Tajez, S.; Esteban, J.I.; Marínó, Z.; Vargas, V.; Lens, S.; Buti, M.; Augustin, S.; Forns, X.; Mínguez, B.; et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. *J. Hepatol.* 2020, 72, 472–480. [CrossRef] [PubMed]
14. De Franchis, R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J. Hepatol.* 2015, 63, 743–752. [CrossRef] [PubMed]
15. Cheung, M.C.M.; Walker, A.J.; Hudson, B.E.; Verma, S.; McLauchlan, J.; Mutimer, D.J.; Brown, A.; Gelson, W.T.H.; MacDonald, D.C.; Agarwal, K.; et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. *J. Hepatol.* 2016, 65, 741–747. [CrossRef] [PubMed]
16. Ziol, M.; Handra-luca, A.; Kettaneh, A.; Christidis, C.; Mal, E.; Kazemi, F.; de Ledinghen, V.; Marcellin, P.; Dhumeaux, D.; Trinchet, J.C.; et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005, 41, 48–54. [CrossRef]
17. Ganne-Carrie’, N.; Zioz, M.; de Ledinghen, Y.; Douvin, C.; Marcellin, P.; Castera, L.; Dhumeaux, D.; Trinchet, J.C.; Beaugard, M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. *Hepatology* 2006, 44, 1511–1517. [CrossRef]
18. Bureau, C.; Metivier, S.; Peron, J.M.; Selves, J.; Robic, M.A.; Gourraud, P.A.; Rouquet, O.; Dupuis, E.; Alric, L.; Vinel, J.P. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. *Aliment. Pharmacol. Therap.* 2008, 27, 1261–1268. [CrossRef]

The authors declare no conflict of interest.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.
19. Vizzutti, F.; Arena, U.; Romanelli, R.G.; Rega, L.; Foschi, M.; Colagrande, S.; Petrarca, A.; Moscarella, S.; Belli, G.; Zignego, A.L.; et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology* 2007, 45, 1250–1297. [CrossRef]

20. Lemoine, M.; Katsahian, S.; Ziol, M.; Nahon, P.; Ganne-Carrie, N.; Kazemi, F.; Grando-Lemaire, V.; Trinchet, J.C.; Beaugrand, M. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. *Aliment. Pharmacol. Ther.* 2008, 28, 1102–1110. [CrossRef]

21. Masuzaki, R.; Tateishi, R.; Yoshida, H.; Goto, E.; Sato, T.; Ohki, T.; Imamura, J.; Goto, T.; Kanai, F.; Kato, N.; et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009, 49, 1954–1961. [CrossRef]

22. Karlas, T.; Benckert, J.; Beer, S.; Keim, V.; Berg, T.; Wiegand, J. Letter: Can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy? *Aliment. Pharmacol. Ther.* 2016, 43, 543–544. [CrossRef]

23. Elsharkavy, A.; Alem, S.A.; Fouad, R.; El Raziky, M.; El Akel, W.; Abd, M.; Tantawi, O.; AbdAllah, M.; Bourliere, M.; Esmat, G. Changes in liver stiffness measurement and fibrosis scores following sofosbuvir based treatment regimens without interferon. *J. Gastroenterol. Hepatol.* 2017, 32, 1624–1630. [CrossRef] [PubMed]

24. Bachofner, J.A.; Valli, P.V.; Kröger, A.; Bergamin, I.; Künzler, P.; Baserga, A.; Braun, D.; Seifert, B.; Moncsek, A.; Fehr, J.; et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int.* 2017, 37, 369–376. [CrossRef]

25. Rinaldi, L.; Guarino, M.; Perrella, A.; Pafundi, P.C.; Valente, G.; Fontanella, L.; Nevola, R.; Guerrera, B.; Iuliano, N.; Imparato, M.; et al. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. *Dig. Dis. Sci.* 2019, 64, 3013–3019. [CrossRef] [PubMed]

26. Singh, S.; Facciorusso, A.; Loomba, R.; Falck-Ytter, Y.T. Magnitude and Kinetics of Decrease in Liver Stiffness after Antiviral Therapy in Patients with Chronic Hepatitis C: A Systematic Review and Meta-analysis. *Clin. Gastroenterol. Hepatol.* 2018, 16, 27–38.e4. [CrossRef]

27. Lens, S.; Alvarado-Tapias, E.; Mariño, Z. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-Associated Cirrhosis. *Gastroenterology* 2017, 153, 1273–1283.e1. [CrossRef]

28. Pons, M.; Simon-Talera, M.; Millan, L.; Ventura-Cots, M.; Santos, B.; Augustin, S.; Genesca, J. Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease. *Dig. Liver Dis.* 2016, 48, 1214–1219. [CrossRef]

29. Ravaioli, F.; Conti, F.; Brillanti, S.; Andreone, P.; Mazzella, G.; Buonfiglioli, F.; Serio, I.; Verrucchi, G.; Bacchi Reggiani, M.L.; Colli, A.; et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. *Dig. Liver Dis.* 2018, 50, 573–579. [CrossRef] [PubMed]

30. Krassenburg, L.A.P.; Maan, R.; Ramji, A.; Manss, M.P.; Cornberg, M.; Wedemeyer, H.; de Knegt, R.J.; Hansen, B.E.; Janssen, H.L.A.; de Man, R.A.; et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. *J. Hepatol.* 2021, 74, 1053–1063. [CrossRef] [PubMed]

31. Romano, A.; Angeli, P.; Piovesan, S.; Noventa, F.; Anastassopoulos, G.; Chemello, L.; Cavalletto, L.; Gambato, M.; Russo, F.P.; Burra, P.; et al. Newly diagnosed Hepatocellular Carcinoma in patients with chronic hepatitis C treated with DAAs: A prospective population study. *J. Hepatol.* 2018, 69, 345–352. [CrossRef] [PubMed]

32. Gaiani, S.; Gramantieri, L.; Venturioli, N.; Piscaglia, F.; Siringo, S.; D’Errico, A.; Zironi, G.; Grigioni, W.; Bolondi, L. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. *J. Hepatol.* 1997, 27, 973–985. [CrossRef]

33. Available online: https://aifa.gov.it/aggiornamento-epatite-c (accessed on 31 January 2020).

34. EASL. Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 2018, 69, 182–236. [CrossRef] [PubMed]

35. Fine, J.P.; Gray, R.J. A proportional hazards model for the distribution of a competing risk. *J. Am. Stat. Assoc.* 1999, 94, 496–509. [CrossRef]